Official numbers appear with a lack of drugs in the UK to their worst level for four years. Britain’s exit from the European Union It is so major that many medications are rare.
Pharmaceutical companies have informed a department health Social Welfare (DHSC) about the disturbances to provide 1938 times during the past year – the highest number since 1967 seen in 2021.
Medicines to treat epilepsy and cystic fibrosis are among those that pharmacists find that it is difficult or impossible to obtain risks to patient health.
The numbers appeared in a new report issued by Nuffield Trust HELTH ThINKTANK, which he obtained under DHSC information laws, which oversee the availability of drugs at the UK level.
The number of show disorders decreased after 2021, to 1,608 in 2022 and 1634 in 2023. But it suddenly rose again last year to 1938.
“This wave of medicine lacks already means that people are struggling to find the medications that their doctors have told that they are necessary for conditions such as epilepsy and cystic fibrosis. It is extremely disturbing that it appears to be rolling completely in the third year,” said Mark Dayan, a Nuffield Trust Policy analyst and the leadership of the Brexit program.
The report says that although drug lack has become a problem worldwide in recent years, the UK faces a “increasing situation” compared to the rest of Europe due to Britain’s exit from the European Union.
“High and disturbing levels of continuous drug deficiency, with no fixed sign of improvement. The UK has achieved the slightest growth of imports in medicines in any G7 country, driven by a decrease in the imports of the European Union,” he adds Thinktank.
The United Nations commercial data, which is analyzed by Dayan and its colleagues, shows that the United Kingdom “has the lowest rise in drug imports in all G7 countries since 2010”.
“The total value [of imports] It has decreased by almost 20 % since 2015, the year that precedes the European Union referendum, according to how medicine supply chains have been turned away from the United Kingdom, “the report says, with” a small sign of stable recovery since then. “
HM revenues and customs data show that there is “a decrease [in imports] He clearly focused on imports from the European Union, adding to the evidence that the new commercial barriers related to Britain from the European Union are a possible explanation. “
In addition, drug exports in the United Kingdom decreased to the European Economic Zone – the 27 states of the European Union in addition to Norway, Iceland and Lesteinstein – in a third since the UK voted in 2016 to leave the European Union.
The National Pharmacy Association expressed its warning earlier this month about “a growing crisis in medical supplies.” All 500 pharmacies included in the survey said they could not dispense with a prescription at least once a day because the drugs were not available.
After promoting the newsletter
“Pharmacies at the acute end of drug lack, and often you have to move away from patients who feel sorrow, frustration and sometimes angry.”
He urged the ministers to allow pharmacists to provide patients as a safe alternative to their usual drugs if not available, to help them manage their condition. He added: “It is especially frustrated that pharmacists are unable to meet a clear need when they have a completely safe and effective solution in their pharmacy.”
Diane warned that with the European Union taking concerted measures to reduce drug deficiency by sharing supplies and increasing its local production, “there are real risks that we will be excluded as the European Union reveals major plans to protect its own supplies.”
He added that Britain’s exit from the European Union “seems to have pushed us to get out of some European supply chains.”
A DHSC spokesman said: “This government has inherited problems in the ongoing global offer, but we have strong measures to alleviate patients’ disruption. We strengthen our local flexibility more by investing up to 520 million pounds to manufacture more medicines, diagnoses and medical techniques in the United Kingdom.
“We are also working closely with NHSOther main organizers and partners to cut the red strip to develop our life science sector, and with international partners to support supply chains. “
